Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
0.249
+0.005 (2.05%)
At close: Jan 21, 2025, 4:00 PM
0.250
+0.001 (0.44%)
After-hours: Jan 21, 2025, 6:59 PM EST
Cellectar Biosciences Stock Forecast
CLRB's stock price has decreased by -93.02% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CLRB stock has a target of 28, which predicts an increase of 11,167.61% from the current stock price of 0.25.
Analyst Consensus: Buy
* Price targets were last updated on Mar 28, 2024.
Analyst Ratings
The average analyst rating for CLRB stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 11, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $14 → $12 | Buy | Maintains | $14 → $12 | +4,728.97% | Nov 19, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $14 | Buy | Reiterates | $14 | +5,533.80% | Oct 11, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $20 → $28 | Strong Buy | Maintains | $20 → $28 | +11,167.61% | Mar 28, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $11 → $12 | Buy | Reiterates | $11 → $12 | +4,728.97% | Mar 28, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
8.24M
EPS This Year
-1.63
from -3.50
EPS Next Year
-0.73
from -1.63
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 33.9M | 104.5M | |||
| Avg | n/a | 8.2M | 25.4M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 1,168.8% | |||
| Avg | - | - | 208.1% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.53 | -0.69 | -0.27 | |||
| Avg | -1.63 | -0.73 | -0.90 | |||
| Low | -1.70 | -0.75 | -1.31 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.